Showing 15 posts of 1079 posts found.

UK AI firm wins share of £140 million funding for lung cancer detection tech

June 18, 2021
Medical Communications AI, CT, NHS, funding, lunch cancer, screening, technology

Artificial intelligence firm Behold.ai has won a share of £140 million in government funding for its red dot lung cancer …

NHS to pilot artificial pancreas for type 1 diabetes

June 17, 2021
NHS, diabetes, insulin, technology, wearable technology

The NHS has announced that artificial pancreases will be available to patients with type 1 diabetes, with up to 1,000 …


Lucida Medical gains CE marking for AI prostate cancer tech

June 1, 2021
Manufacturing and Production AI, MRI, NHS, prostate cancer

Cambridge-based AI company, Lucida Medical, has received CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence …

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

May 11, 2021
Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …

NICE rejects Merck Serono’s Bavencio for urothelial cancer

May 10, 2021
Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …


First approved C5 complement inhibitor recommended by NICE for NHS use

April 15, 2021

NICE has recommended Ultomiris (ravulizumab) for use in the NHS for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult …


The Truth Behind the £1.8 Million Drug

March 31, 2021
Manufacturing and Production FDA, NHS, NICE

As NICE approves the most expensive drug ever for use by the NHS, Jack Goddard takes a look at drug …

NHS agrees on MSD interim colorectal cancer treatment

March 25, 2021
COVID-19, Cancer, MSD, NHS

MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …

AstraZeneca leukaemia treatment recommended for NHS use

March 18, 2021
AstraZeneca, NHS

AstraZeneca has announced today that its oral targeted cancer therapy, Calquence (acalabrutinib), has been recommended by NICE for routine use …


NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

December 8, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …


NICE recommends Lilly’s Emgality for chronic and episodic migraine

November 18, 2020
Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …

NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura

November 12, 2020
Sales and Marketing NHS, NICE, Sanofi, pharma

Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …


NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …


NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

October 22, 2020
Sales and Marketing MSD, NCIE, NHS, keytruda

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …

Latest content